Daniel M. Geynisman, MD, of Fox Chase Cancer Center, discusses the rationale behind the phase 2 RETAIN 1 trial, aimed at evaluating how muscle-invasive bladder cancer is treated. The RETAIN trial explores whether certain patients can safely avoid invasive procedures such as radical surgery or chemoradiation and retain their bladders without compromising long-term outcomes.
RETAIN 1 Trial: Using DNA Damage Repair Mutations to Guide Bladder Cancer Treatment
By Daniel M. Geynisman, MD - Last Updated: January 10, 2025Related Posts
Dr. Plimack details RETAIN, from early findings with neoadjuvant ddMVAC to the evolution of RETAIN-1 and RETAIN-2.
Preliminary results of the study showed promising efficacy and safety with neoadjuvant treatment with DV plus toripalimab.
Drs. Ghatalia and Nizam break down in detail the RETAIN-2 study, a phase 2 trial of risk enabled therapy for MIBC.
Dr. Galsky highlights the latest findings on the impact of pCR on long-term outcomes in the NIAGARA trial.
Dr. Galsky provides comment on the additional efficacy outcomes in patients with MIBC from the CheckMate 274 study.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.